Porownywarka

Semaglutide vs 5-Amino-1MQ side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

Semaglutide5-Amino-1MQ

Udostępnij porównanie peptydów

Wlasciwosc	Semaglutide	5-Amino-1MQ
Kategoria	Redukcja masy	Redukcja masy
Znany tez jako	Ozempic, Wegovy, Rybelsus	5-amino-1-methylquinolinium, NNMT Inhibitor
Zatwierdzony przez FDA	Tak	Nie
Status kliniczny	FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	Preclinical research; no published human trials reported in the supplied source Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Weight loss, appetite control, blood sugar management	Fat metabolism, cellular energy, body composition
Jak dziala	According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.	5-Amino-1MQ is described in the supplied evidence as an inhibitor of NNMT, the enzyme nicotinamide N-methyltransferase. The proposed model is that lowering NNMT activity may affect adipocyte metabolism through nicotinamide, NAD+ and SAM-related pathways, potentially shifting energy handling in fat tissue. The cited mouse work reported increases in intracellular NAD+ and SAM after NNMT inhibition, but the source does not provide human trial confirmation for these effects.
Typowe dawkowanie	1-2.4 mg weekly (after titration) · Once weekly	50-75 mg daily · Once daily, morning · 4-6 weeks on, 2-4 weeks off
Dawkowanie z badań	0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)	20 mg/kg/day (mice) · 4-6 weeks (cycling recommended) · Subcutaneous injection or oral
Typowy czas trwania	Long-term / chronic use	4-6 weeks (cycling recommended)
Podanie	Subcutaneous injection weekly, or oral (Rybelsus)	Subcutaneous injection or oral
Timing	Morning, same day each week With or without food	Morning, fasted With or without food
Poziom dowodów	Zatwierdzone przez FDA	Przedkliniczne
Mozliwe skutki uboczne	Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.) Vomiting Diarrhea +10 więcej Constipation Abdominal pain Headache Fatigue Injection site reactions Hypoglycemia (Source associates this report with insulin/sulfonylureas.) Gallbladder problems Pancreatitis Acute kidney injury Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)	Mild headache (Reported with initial dosing in the supplied source.) Nausea (Listed as a reported side effect by the source.) Increased alertness or jitteriness (Source-reported; may relate to timing concerns about sleep disruption.) +2 więcej Insomnia (Listed as rare in the supplied source.) Elevated blood pressure (Listed as rare in the supplied source.)
Podsumowanie researchu	The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.	The supplied source highlights preclinical work on small-molecule NNMT inhibitors in diet-induced obese mice. In that work, treated animals reportedly lost about 5% of baseline weight over roughly 11 days, had lower white adipose mass and reduced circulating cholesterol, while food intake did not change. The source characterizes the overall evidence base as animal and cell research and states that published human trials demonstrating fat loss, increased energy expenditure or long-term safety were not available. The source separately cautions that vendor-promoted percentages for human fat loss remain unsupported by clinical trial evidence.
Referencje	Źródło Źródło +2 więcej Źródło Źródło	Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Semaglutide

5-Amino-1MQ

Kategoria

Redukcja masy

Znany tez jako

Ozempic, Wegovy, Rybelsus

5-amino-1-methylquinolinium, NNMT Inhibitor

Zatwierdzony przez FDA

Tak

Nie

Status kliniczny

FDA-approved status recorded by the supplied source; it also reports several 2025-2026 indication and formulation updates.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Preclinical research; no published human trials reported in the supplied source

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Weight loss, appetite control, blood sugar management

Fat metabolism, cellular energy, body composition

Jak dziala

According to the supplied description, semaglutide stimulates the GLP-1 receptor. Reported downstream effects include increased insulin secretion when glucose is elevated, decreased glucagon, slower gastric emptying, and hypothalamic appetite signaling. A fatty-acid modification is described as promoting albumin binding and as associated with an approximately 160 hour (about 160 hours) half-life, supporting weekly administration.

5-Amino-1MQ is described in the supplied evidence as an inhibitor of NNMT, the enzyme nicotinamide N-methyltransferase. The proposed model is that lowering NNMT activity may affect adipocyte metabolism through nicotinamide, NAD+ and SAM-related pathways, potentially shifting energy handling in fat tissue. The cited mouse work reported increases in intracellular NAD+ and SAM after NNMT inhibition, but the source does not provide human trial confirmation for these effects.

Typowe dawkowanie

1-2.4 mg weekly (after titration) · Once weekly

50-75 mg daily · Once daily, morning · 4-6 weeks on, 2-4 weeks off

Dawkowanie z badań

0.25mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly, or oral (Rybelsus)

20 mg/kg/day (mice) · 4-6 weeks (cycling recommended) · Subcutaneous injection or oral

Typowy czas trwania

Long-term / chronic use

4-6 weeks (cycling recommended)

Podanie

Subcutaneous injection weekly, or oral (Rybelsus)

Subcutaneous injection or oral

Timing

Morning, same day each week

With or without food

Morning, fasted

With or without food

Poziom dowodów

Zatwierdzone przez FDA

Przedkliniczne

Mozliwe skutki uboczne

Nausea (Common and usually transient; the source says reports vary with dose, duration, and individual health factors.)
Vomiting
Diarrhea

+10 więcej

Constipation
Abdominal pain
Headache
Fatigue
Injection site reactions
Hypoglycemia (Source associates this report with insulin/sulfonylureas.)
Gallbladder problems
Pancreatitis
Acute kidney injury
Thyroid C-cell tumors (Boxed warning; the source lists a contraindication with MTC/MEN 2.)

Mild headache (Reported with initial dosing in the supplied source.)
Nausea (Listed as a reported side effect by the source.)
Increased alertness or jitteriness (Source-reported; may relate to timing concerns about sleep disruption.)

+2 więcej

Insomnia (Listed as rare in the supplied source.)
Elevated blood pressure (Listed as rare in the supplied source.)

Podsumowanie researchu

The source characterizes the clinical literature as extensive. It reports that the SUSTAIN program established blood-sugar control in type 2 diabetes and that SUSTAIN 6 reduced cardiovascular events. For STEP 1, published in the New England Journal of Medicine in 2021, the source describes nearly 2,000 adults without diabetes in a randomized trial: at a 68 week endpoint, semaglutide 2.4 mg had 14.9 % mean weight loss versus 2.4 % with placebo, and most participants lost at least 5 %. It characterizes this as large randomized, placebo-controlled research rather than pilot data. Gastrointestinal effects, including nausea, vomiting, and constipation, were reported as most prominent during escalation; the source also reports an oral weight-management version as approved.

The supplied source highlights preclinical work on small-molecule NNMT inhibitors in diet-induced obese mice. In that work, treated animals reportedly lost about 5% of baseline weight over roughly 11 days, had lower white adipose mass and reduced circulating cholesterol, while food intake did not change. The source characterizes the overall evidence base as animal and cell research and states that published human trials demonstrating fat loss, increased energy expenditure or long-term safety were not available. The source separately cautions that vendor-promoted percentages for human fat loss remain unsupported by clinical trial evidence.

Referencje

Źródło Źródło

+2 więcej

Źródło Źródło

Pełny profil

Zobacz szczegóły